@article{JTD1540,
author = {Xiuyi Zhi and Wen Gao and Baohui Han and Yue Yang and Hui Li and Deruo Liu and Changli Wang and Gong Min and Hao Long and James R. Rigas and Mark Carey and Thierry Jahan and Amanda Sammann and Joseph Reza and Daoyuan Wang and Michael J. Mann and David M. Jablons and Jianxing He and for the China Clinical Trials Consortium},
title = {VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer},
journal = {Journal of Thoracic Disease},
volume = {5},
number = {5},
year = {2013},
keywords = {},
abstract = {Background: To evaluate the safety and tolerability of docetaxel/carboplatin regimen in the post-operative setting of patients with non-small cell lung cancer (NSCLC).
Methods: Enrolment of 133 patients with stage Ib - IIIa NSCLC was undertaken in an open-label, single arm study to assess the safety and tolerability of docetaxel (75 mg/kg) and carboplatin (AUC 5.5) administered for 3 cycles after resection for curative intent. The primary endpoint of the study was safety, as reflected by a febrile neutropenia rate of },
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/1540}
}